GlobeNewswire by notified

SKEL fjárfestingafélag hf.: AGM 9 March 2023 - Candidates to the Board of Directors and Nomination Committee

Share

SKEL fjárfestingafélag hf.'s Annual General Meeting will be held on Thursday, 9 March 2023 at 16:00 in the Ballroom at the Reykjavík Edition, Austurbakki 2, 101 Reykjavík.

The deadline for declaring candidacy for the Board of Directors has passed. The following are the candidates for the Board of Directors of SKEL:

  • Birna Ósk Einarsdóttir
  • Guðni Rafn Eiríksson
  • Jón Ásgeir Jóhannesson
  • Nanna Björk Ásgrímsdóttir
  • Sigurður Kristinn Egilsson

According to the Company's Articles of Association the Annual General Meeting elects five members for the Board of Directors and therefore the candidates will be elected without ballot at the meeting. Further information on each candidate and the Nomination Committee’s proposal can be found in the attached document and on SKEL's website: https://skel.is/en/shareholders/shareholder-meetings

The deadline for declaring candidacy for the Nomination Committee has also passed. The following are candidates for the Nomination Committee:

  • Almar Þór Möller
  • Álfheiður Eva Óladóttir

According to the code of conduct for SKEL Nomination Committee two committee members shall be elected by the shareholders’ meeting and the new Board shall elect one of their own following the shareholders’ meeting. Consequently, Almar and Álfheiður, will be elected to the Nomination Committee without a ballot at the meeting.

All documents for the AGM can be found on the company’s website: https://skel.is/en/shareholders/shareholder-meetings

Shareholders can register for the meeting at the meeting location, from 15:00, on the meeting date.

For further information please contact Ásgeir Helgi Reykfjörð Gylfason, CEO, fjarfestar@skel.is

Attachments

To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.

About GlobeNewswire by notified

GlobeNewswire by notified
GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://notified.com

GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire by notified

Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire by notified

Intervest Offices & Warehouses NV: Press release – Persbericht – Communiqué de presse: openbaarmaking over transparantiekennisgeving19.4.2024 18:00:00 CEST | Press release

Geachte mevrouw, meneer, Gelieve hierbij de links te vinden naar het recente persbericht van Intervest Offices & Warehouses betreffende de openbaarmaking over transparantiekennisgeving. Dear Madam, Sir, Please find hereunder the links to Intervest Offices & Warehouses’ latest press release regarding the publication of a transparency notification. Attachment NL_transparency notification_20240419

23/2024・Trifork Group AG – Shareholders approve all resolutions at the Annual General Meeting 202419.4.2024 17:34:19 CEST | Press release

Company announcement no. 23 / 2024 Schindellegi, Switzerland – 19 April 2024 Shareholders approve all resolutions at the Annual General Meeting 2024 The shareholders of Trifork Group AG (“Trifork“) today approved all resolutions proposed by the Board of Directors at Trifork’s Annual General Meeting 2024 (the “AGM“) which was held at Grabenstrasse 2, 6430 Baar, Switzerland. Dividend payment The shareholders approved the Board of Directors’ proposal to pay a gross dividend of EUR 0.10 per share (equivalent to CHF 0.10 per share) by making a payout from capital contribution reserves to the shareholders. The total gross dividend paid out amounts to CHFk 1,932, equivalent to DKKk 14,809, as calculated per the exchange rate published by the Swiss Federal Customs Administration as of 19 April 2024. The payout from capital contribution reserves is declared in CHF and paid out in DKK. Composition of the Board of Directors The shareholders re-elected Julie Galbo as Chairperson of the Board of Di

Havila Shipping ASA: Årsrapport 202319.4.2024 17:06:25 CEST | Pressemelding

Styret i Havila Shipping ASA har i dag godkjent regnskap og årsrapport for 2023 for konsern og morselskap. Resultatregnskap og balanser er i samsvar med foreløpig regnskap offentliggjort 27. februar 2024. Kontakter: Administrerende direktør Njål Sævik, +47 909 35 722 Finansdirektør Arne Johan Dale, +47 909 87 706 Denne opplysningen er informasjonspliktig etter verdipapirhandelloven §5-12 Vedlegg HAVI-20235967007LIEEXZXFJ8876-2023-12-31-no

Havila Shipping ASA : Annual Report 202319.4.2024 17:06:25 CEST | Press release

Today, the Board of Directors of Havila Shipping ASA has approved the financial statements for 2023 for both the Group and the parent company. The accounts are in line with preliminary accounts released on 27 February 2024. Contacts: Chief Executive Officer Njål Sævik, +47 909 35 722 Chief Financial Officer Arne Johan Dale, +47 909 87 706 This information is subject to the disclosure requirements pursuant to Section 5-12 the Norwegian Securities Trading Act Attachments HAVI-20235967007LIEEXZXFJ8876-2023-12-31-no

Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons19.4.2024 17:05:00 CEST | Press release

Company announcement – No. 23 / 2024 Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons Copenhagen, Denmark, April 19, 2024 – Zealand Pharma A/S (“Zealand”) (NASDAQ: ZEAL) (CVR-no. 20 04 50 78), a Copenhagen-based biotechnology company focused on the discovery and development of innovative peptide-based medicines, has received information on transactions in Zealand's shares or related securities conducted by persons discharging managerial responsibilities and/or their closely associated persons and hereby publishes the information on such transactions. Please see the attached file(s). # # # About Zealand Pharma A/S Zealand Pharma A/S (Nasdaq: ZEAL) ("Zealand") is a biotechnology company focused on the discovery and development of peptide-based medicines. More than 10 drug candidates invented by Zealand have advanced into clinical development, of which two have reached the market and

HiddenA line styled icon from Orion Icon Library.Eye